Paul CPA - Mosaic Immunoengineerin CFO, VP
| CPMV Stock | USD 1.00 0.39 63.93% |
Insider
Paul CPA is CFO, VP of Mosaic Immunoengineering
| Age | 55 |
| Phone | 657-208-0890 |
| Web | https://www.mosaicie.com |
Mosaic Immunoengineerin Management Efficiency
The company has return on total asset (ROA) of (4.2041) % which means that it has lost $4.2041 on every $100 spent on assets. This is way below average. Mosaic Immunoengineerin's management efficiency ratios could be used to measure how well Mosaic Immunoengineerin manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | INSIDER Age | ||
| Linda JD | Northwest Biotherapeutics | 67 | |
| Jean Davis | Northwest Biotherapeutics | 51 | |
| Stephen JD | Geron | 74 | |
| , MBA | Northwest Biotherapeutics | 64 | |
| David Innes | Northwest Biotherapeutics | N/A | |
Management Performance
| Return On Asset | -4.2 |
Mosaic Immunoengineering Leadership Team
Elected by the shareholders, the Mosaic Immunoengineerin's board of directors comprises two types of representatives: Mosaic Immunoengineerin inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mosaic. The board's role is to monitor Mosaic Immunoengineerin's management team and ensure that shareholders' interests are well served. Mosaic Immunoengineerin's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mosaic Immunoengineerin's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jay Carlson, Sr Relations | ||
| Steven King, Pres Chairman | ||
| Cyril Empig, Head Devel | ||
| Marvin MD, Head ImmunoOncology | ||
| Nicole Steinmetz, Acting Director | ||
| Paul CPA, CFO, VP | ||
| Joseph MPH, Head Operations |
Mosaic Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Mosaic Immunoengineerin a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -4.2 | |||
| Current Valuation | 10.22 M | |||
| Shares Outstanding | 7.24 M | |||
| Shares Owned By Insiders | 88.73 % | |||
| Price To Book | 9.33 X | |||
| EBITDA | (3.52 M) | |||
| Net Income | (3.68 M) | |||
| Cash And Equivalents | 205.99 K | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 735.15 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mosaic OTC Stock Analysis
When running Mosaic Immunoengineerin's price analysis, check to measure Mosaic Immunoengineerin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mosaic Immunoengineerin is operating at the current time. Most of Mosaic Immunoengineerin's value examination focuses on studying past and present price action to predict the probability of Mosaic Immunoengineerin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mosaic Immunoengineerin's price. Additionally, you may evaluate how the addition of Mosaic Immunoengineerin to your portfolios can decrease your overall portfolio volatility.